{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T19:30:05Z","timestamp":1793820605965,"version":"4.6.1"},"reference-count":37,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Mathematical Biosciences"],"published-print":{"date-parts":[[2026,12]]},"DOI":"10.1016\/j.mbs.2026.109805","type":"journal-article","created":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T22:50:37Z","timestamp":1789253437000},"page":"109805","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Revisiting Fulvestrant Dosing: Biomarker-Driven Mathematical PK\/PD Modeling and Dosing Optimization in Estrogen Receptor\u2013Positive Breast Cancer"],"prefix":"10.1016","volume":"402","author":[{"ORCID":"https:\/\/orcid.org\/0009-0002-3222-8897","authenticated-orcid":false,"given":"Nikhil","family":"Srinivasan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.mbs.2026.109805_bib0002","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1007\/s40487-017-0046-2","article-title":"A review of Fulvestrant in breast cancer","volume":"5","author":"Nathan","year":"2017","journal-title":"Oncol. Ther."},{"issue":"4","key":"10.1016\/j.mbs.2026.109805_bib0003","doi-asserted-by":"crossref","DOI":"10.1002\/mco2.181","article-title":"Small molecule inhibitors targeting the cancers","volume":"3","author":"Liu","year":"2022","journal-title":"MedComm"},{"key":"10.1016\/j.mbs.2026.109805_bib0004","series-title":"Precision Oncology","year":"2023"},{"issue":"17","key":"10.1016\/j.mbs.2026.109805_bib0005","first-page":"3384","article-title":"Lessons from phase I clinical trials in oncology: the importance of pharmacodynamic end points","volume":"21","author":"Ratain","year":"2003","journal-title":"J. Clin. Oncol."},{"issue":"5","key":"10.1016\/j.mbs.2026.109805_bib0006","first-page":"86","article-title":"Pharmacodynamic biomarkers in oncology: development and implementation","volume":"15","author":"Schellens","year":"2016","journal-title":"Nat. Rev. Drug Discovery"},{"key":"10.1016\/j.mbs.2026.109805_bib0007","doi-asserted-by":"crossref","first-page":"1","DOI":"10.5402\/2012\/590626","article-title":"Pharmacodynamic modelling of biomarker data in oncology","volume":"2012","author":"Jackson","year":"2012","journal-title":"ISRN. Pharmacol."},{"issue":"3","key":"10.1016\/j.mbs.2026.109805_bib0008","doi-asserted-by":"crossref","first-page":"619","DOI":"10.3390\/cancers16030619","article-title":"Oral SERD, a novel endocrine therapy for estrogen receptor-positive breast cancer","volume":"16","author":"Neupane","year":"2024","journal-title":"Cancers"},{"issue":"6","key":"10.1016\/j.mbs.2026.109805_bib0009","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1016\/j.clbc.2014.06.005","article-title":"A good drug made better: the fulvestrant dose-response story","volume":"14","author":"Robertson","year":"2014","journal-title":"Clin. Breast. Cancer"},{"issue":"2","key":"10.1016\/j.mbs.2026.109805_bib0010","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1016\/j.pathol.2023.10.014","article-title":"Predictive and prognostic biomarkers in breast tumours","volume":"56","author":"Krystel-Whittemore","year":"2024","journal-title":"Pathology"},{"issue":"2","key":"10.1016\/j.mbs.2026.109805_bib0011","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1038\/nrd.2016.211","article-title":"Induced protein degradation: an emerging drug discovery paradigm","volume":"16","author":"Lai","year":"2017","journal-title":"Nat. Rev. Drug Discovery"},{"issue":"3","key":"10.1016\/j.mbs.2026.109805_bib0012","doi-asserted-by":"crossref","first-page":"209","DOI":"10.3322\/caac.21660","article-title":"Global Cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CACancer J. Clin."},{"key":"10.1016\/j.mbs.2026.109805_bib0013","series-title":"Breast Cancer","article-title":"Subtypes of breast cancer","author":"Orrantia-Borunda","year":"2022"},{"issue":"6","key":"10.1016\/j.mbs.2026.109805_bib0014","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1080\/13543784.2021.1983542","article-title":"Latest generation estrogen receptor degraders for the treatment of hormone receptor-positive breast cancer","volume":"31","author":"Chen","year":"2022","journal-title":"Expert. Opin. Investig. Drugs"},{"key":"10.1016\/j.mbs.2026.109805_bib0015","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1038\/s41523-023-00523-4","article-title":"An emerging generation of endocrine therapies in breast cancer: a clinical perspective","volume":"9","author":"Patel","year":"2023","journal-title":"NPJ. Breast. Cancer"},{"key":"10.1016\/j.mbs.2026.109805_bib0016","doi-asserted-by":"crossref","first-page":"e8","DOI":"10.1200\/EDBK_237419","article-title":"Redrawing the lines: the next generation of treatment in metastatic breast cancer","volume":"39","author":"Savard","year":"2019","journal-title":"Am. Soc. Clin. Oncol. Educ. Book."},{"key":"10.1016\/j.mbs.2026.109805_bib0017","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1159\/000444451","article-title":"Overcoming resistance to endocrine therapy in breast cancer: new approaches to a nagging problem","volume":"25","author":"Luqmani","year":"2016","journal-title":"Med. Princ. Pract."},{"issue":"6","key":"10.1016\/j.mbs.2026.109805_bib0018","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1038\/s41568-018-0001-z","article-title":"Structural underpinnings of oestrogen receptor mutations in endocrine therapy resistance","volume":"18","author":"Katzenellenbogen","year":"2018","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.mbs.2026.109805_bib0019","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.coph.2018.04.009","article-title":"Mechanisms of resistance in estrogen receptor positive breast cancer: overcoming resistance to tamoxifen\/aromatase inhibitors","volume":"41","author":"Mills","year":"2018","journal-title":"Curr. Opin. Pharmacol."},{"key":"10.1016\/j.mbs.2026.109805_bib0020","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1111\/j.1399-0004.2008.01111.x","article-title":"Estrogen receptor status in CHEK2-positive breast cancers: implications for chemoprevention","volume":"75","author":"Cybulski","year":"2009","journal-title":"Clin. Genet."},{"issue":"5","key":"10.1016\/j.mbs.2026.109805_bib0021","doi-asserted-by":"crossref","first-page":"1858","DOI":"10.1073\/pnas.96.5.1858","article-title":"Proteasome-dependent degradation of the Human estrogen receptor","volume":"96","author":"Nawaz","year":"1999","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"issue":"4","key":"10.1016\/j.mbs.2026.109805_bib0022","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1002\/1097-0142(20000815)89:4<817::AID-CNCR14>3.0.CO;2-6","article-title":"ICI 182,780 (Faslodex): development of a novel, 'Pure' Antiestrogen","volume":"89","author":"Howell","year":"2000","journal-title":"Cancer"},{"key":"10.1016\/j.mbs.2026.109805_bib0023","doi-asserted-by":"crossref","first-page":"S7","DOI":"10.1038\/sj.bjc.6601630","article-title":"Fulvestrant: pharmacokinetics and pharmacology","volume":"90","author":"Robertson","year":"2004","journal-title":"Br. J. Cancer"},{"issue":"3","key":"10.1016\/j.mbs.2026.109805_bib0024","doi-asserted-by":"crossref","first-page":"363","DOI":"10.2165\/11204810-000000000-00000","article-title":"Fulvestrant","volume":"71","author":"Croxtall","year":"2011","journal-title":"Drugs"},{"key":"10.1016\/j.mbs.2026.109805_bib0025","series-title":"FDA Product Label, Reference ID: 4435906","year":"2019"},{"issue":"7","key":"10.1016\/j.mbs.2026.109805_bib0026","first-page":"2920","article-title":"Breast cancer: molecular mechanisms of underlying resistance and therapeutic approaches","volume":"12","author":"Tufail","year":"2022","journal-title":"Am. J. Cancer Res."},{"issue":"10","key":"10.1016\/j.mbs.2026.109805_bib0027","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1001\/jamaoncol.2016.1279","article-title":"Prevalence of ESR1 mutations in cell-free DNA and outcomes in metastatic breast cancer: a secondary analysis of the BOLERO-2 clinical trial","volume":"2","author":"Chandarlapaty","year":"2016","journal-title":"Jama Oncol."},{"issue":"25","key":"10.1016\/j.mbs.2026.109805_bib0028","doi-asserted-by":"crossref","first-page":"2961","DOI":"10.1200\/JCO.2016.67.3061","article-title":"Plasma ESR1 mutations and the treatment of estrogen receptor-positive advanced breast cancer","volume":"34","author":"Fribbens","year":"2016","journal-title":"J. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.mbs.2026.109805_bib0029","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1186\/s13058-021-01462-3","article-title":"ESR1 Mutation as an emerging clinical biomarker in metastatic hormone receptor-positive breast cancer","volume":"23","author":"Brett","year":"2021","journal-title":"Breast. Cancer Res."},{"issue":"22","key":"10.1016\/j.mbs.2026.109805_bib0030","doi-asserted-by":"crossref","first-page":"5121","DOI":"10.1158\/1078-0432.CCR-15-0360","article-title":"Efficacy of SERD\/SERM hybrid-CDK4\/6 inhibitor combinations in models of endocrine therapy-resistant breast cancer","volume":"21","author":"Wardell","year":"2015","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.mbs.2026.109805_bib0031","doi-asserted-by":"crossref","DOI":"10.1038\/ncomms11579","article-title":"Heterogeneity and clinical significance of ESR1 mutations in ER-positive metastatic breast cancer patients receiving fulvestrant","volume":"7","author":"Spoerke","year":"2016","journal-title":"Nat. Commun."},{"issue":"25","key":"10.1016\/j.mbs.2026.109805_bib0032","doi-asserted-by":"crossref","first-page":"2961","DOI":"10.1200\/JCO.2016.67.3061","article-title":"Plasma ESR1 mutations and the treatment of estrogen receptor-positive advanced breast cancer","volume":"34","author":"Fribbens","year":"2016","journal-title":"J. Clin. Oncol.: Off. J. Am. Soc. Clin. Oncol."},{"issue":"4","key":"10.1016\/j.mbs.2026.109805_bib0033","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1111\/bcpt.13944","article-title":"BCPT 2023 policy for experimental and clinical studies","volume":"133","author":"Tveden-Nyborg","year":"2023","journal-title":"Basic Clin. Pharmacol. Toxicol."},{"issue":"9","key":"10.1016\/j.mbs.2026.109805_bib0034","doi-asserted-by":"crossref","first-page":"3477","DOI":"10.1039\/D2CS00114D","article-title":"Translational PK\u2013PD for targeted protein degradation","volume":"51","author":"Bartlett","year":"2022","journal-title":"Chem. Soc. Rev."},{"issue":"3","key":"10.1016\/j.mbs.2026.109805_bib0035","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1007\/s10549-019-05498-0","article-title":"Correction to: pharmacokinetic and pharmacodynamic analysis of fulvestrant in preclinical models of breast cancer to assess the importance of its estrogen receptor-\u03b1 degrader activity in antitumor efficacy","volume":"179","author":"Wardell","year":"2020","journal-title":"Breast. Cancer Res. Treat."},{"issue":"5","key":"10.1016\/j.mbs.2026.109805_bib0036","doi-asserted-by":"crossref","first-page":"2022","DOI":"10.1096\/fj.14-265637","article-title":"A kinetic model identifies phosphorylated estrogen receptor-\u03b1 (ER\u03b1) as a critical regulator of er\u03b1 dynamics in breast cancer","volume":"29","author":"Tian","year":"2015","journal-title":"FASEB J."},{"issue":"1","key":"10.1016\/j.mbs.2026.109805_bib0037","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1007\/s10549-011-1947-7","article-title":"Dose-dependent change in biomarkers during neoadjuvant endocrine therapy with Fulvestrant: results from NEWEST, a randomized phase II study","volume":"133","author":"Kuter","year":"2012","journal-title":"Breast. Cancer Res. Treat."},{"issue":"2","key":"10.1016\/j.mbs.2026.109805_bib0039","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1158\/2159-8290.CD-22-1387","article-title":"ESR1 F404 Mutations and acquired resistance to fulvestrant in ESR1-mutant breast cancer","volume":"14","author":"Kingston","year":"2024","journal-title":"Cancer Discov."}],"container-title":["Mathematical Biosciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0025556426001951?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0025556426001951?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T19:10:20Z","timestamp":1793819420000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0025556426001951"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,12]]},"references-count":37,"alternative-id":["S0025556426001951"],"URL":"https:\/\/doi.org\/10.1016\/j.mbs.2026.109805","relation":{},"ISSN":["0025-5564"],"issn-type":[{"value":"0025-5564","type":"print"}],"subject":[],"published":{"date-parts":[[2026,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Revisiting Fulvestrant Dosing: Biomarker-Driven Mathematical PK\/PD Modeling and Dosing Optimization in Estrogen Receptor\u2013Positive Breast Cancer","name":"articletitle","label":"Article Title"},{"value":"Mathematical Biosciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.mbs.2026.109805","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"109805"}}